Finally, multiple sets of urinary (NGAL, α1-microglobulin, KIM-1, H-FABP, MCP-1) and plasma (fibroblast growth factor 23 (FGF23)) biomarkers have been discovered that are correlated to parameters of ADPKD disease severity, and may be associated with treatment response to lanreotide [16,17]. This evidence concerns the gene LCN2 and autosomal dominant polycystic kidney disease.